First-in-Human gene therapy tested for blinding eye disease
NCT ID NCT07311863
Summary
This is a very early study to check if a new gene therapy called UGX202 is safe for people with advanced retinitis pigmentosa (RP), a disease that causes severe vision loss. Six patients with very low vision will receive a single injection of the therapy into one eye and be monitored for a year. The main goal is to see if the treatment is safe, while also looking for any early signs that it might help preserve or improve vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA (RP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eye & ENT Hospital of Fudan University
Shanghai, Shanghai Municipality, 200031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.